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ABSTRACT 
LONGITUDINAL INVESTIGATION OF DISPARITY VERGENCE IN  
YOUNG ADULT CONVERGENCE INSUFFICIENCY PATIENTS 
 
by 
Patrick C. Crincoli 
Vergence is a form of eye movement in which the eyes move in opposite directions to 
minimize retinal disparity. It allows an object at different distances from a viewer to appear 
single during binocular vision by centering the image on the fovea of each retina. 
Convergence insufficiency (CI) is a binocular disfunction in which blurry and double 
vision is a symptom. Office-based Vergence/Accommodative Therapy (OBVAT) has been 
shown to be effective in treating CI. A randomized clinical trial was designed to study fifty 
participants with CI before and after therapy using randomized therapy treatment (active 
and placebo), standardized clinical definitions, and a masked clinician to measure clinical 
outcomes. A haploscope was used to independently show stimuli to the left and right eye 
of the participants. A video-based eye tracker was used to capture eye-movement data, and 
a custom MATLAB program was used to analyze the following data parameters: latency, 
time to peak velocity, peak velocity, and final amplitude. Eye-movement data parameters 
significantly improved post OBVAT when comparing baseline and post treatment results. 
The results after Office-Based Placebo Therapy (OBPT) were compared to OBVAT 
results, and a statically significant difference was found. Results support that OBVAT leads 
to a significant improvement in vergence dynamics post therapy compared to baseline 
measurements.
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CHAPTER 1 
INTRODUCTION 
 
1.1 Objective 
The objective of this study is to determine the effectiveness of office-based 
vergence/accommodation therapy (OBVAT) compared to office-based placebo therapy 
(OBPT) for participants with symptomatic convergence insufficiency (CI). Clinical 
measures currently used to diagnosis and quantify convergence insufficiency by 
optometrists are employed in this randomized clinical trial to evaluate therapy 
effectiveness. Additionally, metrics from eye movements captured with an assessment 
protocol using a haploscope are utilized to demonstrate therapy effectiveness. The next few 
sections will give important background information describing the human visual, 
oculomotor, and vergence systems, as well as convergence insufficiency and the 
Convergence Insufficiency Treatment Trial, a related study on OBVAT and OBPT. 
 
1.2 The Visual System 
Sight is a critical sense for the modern human, used to examine one’s surrounding, reading, 
learning and more. Sight is made possible by a complex visual system dependent on a pair 
of light-sensitive organs, the eyes. A thin layer covers and lines the eye called the 
conjunctiva, a mucus membrane [1]-[4]. The eye is composed of three layers: the sclera 
and cornea, the choroid, and the retina [1]-[4]. The sclera is the white outer layer of the 
eye, surrounding it and giving it shape [1]-[4]. The cornea is the front protective and 
refractive outer layer of the eye, which helps to focus light as it enters the eye [1]-[4]. The 
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choroid is a pigmented highly vascularized middle layer providing nutrients to the eye [1]-
[4]. The retina, the inner layer of the eye, receives light and converts it to neural signals 
[1]-[4]. Figure 1.1 shows the basic anatomy of the eye. 
  
Figure 1.1 Diagram of basic eye anatomy. 
Source: [1] 
 
 Light enters and is focused by the cornea. The pupil is a hole in the eye which 
allows light to pass to the back of the eye. The iris controls the amount of light that enters 
the pupil. The ciliary body controls the lens to focus light onto the macula, a region on the 
back of the eye and retina [1],[3],[4]. At the center of the macula is the fovea, surrounded 
by the parafoveal region. The fovea is responsible for high acuity vision and has a high 
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concentration of photoreceptors, especially cones [3],[4]. Figure 1.2 shows the path of light 
entering the eye as well as the anatomy of the eye. 
 
Figure 1.2 Diagram of light entering the eye with detail of retina. 
Source: [4] 
 
The retina is composed of three groups of cells: photoreceptors, interneurons, and 
ganglion cells [4]-[6]. Photoreceptors are the outer layer of cells which transduce light to 
an electrical signal. There are two types of photoreceptors, rods and cones. Rods have a 
low acuity and high sensitivity, amplifying light signals more than cones and functioning 
in dim light [4]. Cones have a high acuity and low sensitivity, functioning in day light 
enabling form and color perception [4]. Interneurons help transmit signals from 
photoreceptors to the ganglion cells. There are three types of interneurons: bipolar cells, 
amacrine cells, and horizontal cells [4],[5]. Ganglion cells respond to receptive fields, of 
which there are a multitude [4]. Figure 1.3 shows a diagram of the cells that make up the 
retina. 
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Figure 1.3 Diagram of the retina and the contained cell types. 
Source [5] 
 
Signals from the ganglion cells travel to the optic nerve [4]-[8]. The neural pathway 
from the eyes to the brain is called the afferent neural pathway. The optic nerve travels to 
the optic chiasm in the hypothalamus where half the axons from each optic nerve travel to 
the ipsilateral and the other half to the contralateral sides of the brain [4],[6]-[8]. The 
images from the left and right eye must be fused into a single and clear image. From here 
signals are transmitted to the lateral geniculate nucleus and finally the primary visual cortex 
in the occipital lobe where high-level visual processing occurs [4],[6]-[8] (Fig 1.4).  
 
Figure 1.4 Diagram of the visual pathway. 
Source: [7] 
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1.3 The Oculomotor System 
The eye rotates within the orbit allowing for motion. Movement of the eye allows the fovea 
to be directed onto an area of interest and keep it steady [9],[10]. The eye moves using six 
muscles: the superior rectus, inferior rectus, medial rectus, lateral rectus, inferior oblique, 
and superior oblique [9],[10] (Fig 1.5). These muscles are controlled by three cranial 
nerves, efferent neural pathways sending signals from the brain to the muscles [9],[11]. 
The superior and inferior rectus move the eye upwards and downwards respectively 
[9],[10]. The medial rectus and lateral rectus move the eyes horizontally towards and away 
from the center of the body respectively [9],[10]. The superior and inferior oblique move 
the eyes clockwise and counterclockwise respectively [9],[10]. Eye rotation can be 
measured using diopters (Δ), degrees (°), or meter-angles. These muscles work together 
through different control systems to move the eye. 
 
Figure 1.5 Diagram of the six eye muscles that control eye movement. 
Source: [9] 
 
 There are six neuronal control systems used to keep the fovea on target. These are: 
saccadic eye movements, smooth pursuit movements, vergence movements, vestibulo-
ocular movements, optokinetic movements, and the fixation system [4],[11],[12]. Smooth 
pursuit movements keep an image of a moving target on the fovea. Vestibulo-ocular 
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movements hold images still on the retina during head tilt using the vestibular system of 
the inner ear. Optokinetic movements hold images during sustained head rotation and are 
driven by visual stimuli. The fixation system holds eyes still, requiring active suppression 
of eye movement. Saccadic eye movements shift the fovea rapidly to a visual target in the 
periphery. Vergence movements move the eyes in opposite directions so an image is 
positioned on both foveae. Saccades are conjunctive (version), eye movements, as both 
eyes move in the same direction, whereas vergence movements are disjunctive, as the eyes 
move in opposite directions. Horizontal saccades and vergence movements use the same 
muscles, the medial and lateral recti [4],[11],[12]. 
 
1.4 The Vergence System 
Humans use both eyes, binocular vision, to perceive depth [4],[11],[12]. The distance 
between each eye, inter pupillary distance (IPD), causes two distinct images to be captured, 
one by each eye. The brain merges these two images into a three-dimensional image. The 
final effect is called stereopsis. Fusion occurs when an object appears on the same spot on 
each retina allowing it to appear single. Saccades are used to move the eyes side to side 
conjunctively to focus on a target without accounting for the depth/distance from the 
subject [4],[11],[12]. Distinctly, vergence movements are used to move the eyes 
disjunctively to maintain eye alignment on a target at a depth/distance from the subject 
[4],[11],[12]. 
 There are two types of vergence eye movements, convergence and divergence 
[4],[11],[12]. In convergence, the eyes move inwards towards a target closer to the subject. 
In divergence the eyes move outwards towards a target further from the subject. There are 
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four types of vergence: fusional, accommodative, proximal, and tonic [4],[11],[12]. 
Fusional vergence uses a disparity cue, the distance difference between an object on each 
retina. Accommodative vergence uses a blur cue, caused by focal length. Proximal 
vergence uses a combination of monocular cues, such as relative size, texture gradients, 
lighting/shading, perspective, occlusion, and motion parallax. Tonic vergence is the resting 
state of the eyes with no stimuli. The resting state of the eyes is also called the phoria. 
Phoria has different classifications: orthophoria, esophoria, exophoria, hyperphoria, or 
cyclophoria [4],[11],[12]. Heterophoria is a generic term used to describe conditions in 
which the eyes tend to drift from a target when the eyes are left without stimuli, dissociated, 
open-looped [13]-[17]. Orthophoria is when the eyes do not drift open-looped. Esophoria, 
exophoria, hyperphoria, and cyclophoria are the tendencies for the eyes to drift inwards, 
outwards, up or downwards, or clockwise or counterclockwise respectively [4],[11],[12]. 
 In the literature, there is a large volume of research into the model-representation 
of the neural control of the disparity-vergence system [18]-[31]. Vergence can be defined 
with two systems, a fast-fusional phasic system (FFPS) and a slow-fusional tonic system 
(SFTS) [18]-[23]. The SFTS is the tonic vergence and phoria. The FFPS includes fusional, 
accommodative, and proximal vergence. One model of FFPS is the Dual Mode Model. In 
the Dual Mode Model there are two components, the fusion initiating component (FIC) 
and the fusion sustaining component (FSC) [18]-[23]. The FIC is preprogrammed 
component that allows the eyes to quickly move to the general position of the target [18]-
[23]. The FSC is the feedback-controlled component that is slower and more accurate [18]-
[23]. The FIC more substantially governs the velocity components of vergence movements 
(time to peak velocity, peak velocity and response amplitude) [18]-[23],[26],[30]. The FSC 
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more substantially governs the final position of the eyes fixated on the target (final 
amplitude) [18]-[23],[26],[30]. Figure 1.6 is a diagrammatic representation of the Dual 
Mode Model. 
 
Figure 1.6 Diagram of the Dual Mode Model. 
Source: [18] 
 
 
1.5 Convergence Insufficiency 
Binocular dysfunctions are conditions in which the eyes do not function correctly due to 
difficulty working together as a team. Convergence insufficiency (CI) is a specific 
binocular dysfunction, in which the eyes do not rotate sufficiently inward to maintain 
fusion of an image, especially with objects near to the person. CI affects approximately 5% 
of the human population, and over 50% of the traumatic brain injury (TBI) population [32]-
[40]. Symptoms of CI can include double or blurry vision, headache, dizziness, or nausea 
when performing visual tasks close to the face [41]. Typically, a person with CI will have 
exophoria greater at near than at distance and one or both eyes will drift outward while 
working at near. CI can only be diagnosed by an eye care professional. Every routine eye 
examination will detect CI if the proper tests are done. In some routine eye examinations, 
the doctor may choose not to do any binocular vision testing. When this inadequate exam 
is performed, CI will not be detected. Standard measures of CI include a high score on the 
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Convergence Insufficiency Symptom Survey (CISS) (see APPENDIX A), a reduced near 
point of convergence (NPC), and a low positive fusional vergence (PFV). CISS is a survey 
intended to quantify symptoms of CI. Each response is rated from 0 to 4 with 4 as the 
highest frequency of symptom (always). There are 15 items which are totaled to get the 
CISS score. The lowest possible score is 0 (least symptoms) and the highest possible score 
is 60 (most symptoms). A score of 16 or higher has been found to indicate symptomatic CI 
in children, and a score of 21 or higher has been found to indicate symptomatic CI in adults. 
Treatments for CI include: home-based therapy solutions including pencil push-ups, or 
office-based vision therapy, or surgery rarely [32]-[40]. 
 
1.6 Convergence Insufficiency Treatment Trial 
The Convergence Insufficiency Treatment Trial (CITT) led by study chair Dr. Mitchell 
Scheiman, O.D., Ph.D. assessed four different CI therapy methods: office-based 
vergence/accommodative therapy with home reinforcement (OBVAT), home-based pencil 
pushups (HBPP), home-based computer vergence/accommodative therapy and pencil 
pushups (HBCVAT+), and office-based placebo therapy (OBPT) [42]. CITT was a large-
scale stage 3 randomized clinical trial funded through the National Institutes of Health 
(NIH) with 221 children participants ranging from 9-18 years of age. After 12 weeks of 
therapy, the OBVAT group had a statistically significant (P<0.001) decrease in CISS score, 
greater than the other therapy groups. Further, the OBVAT group, compared to other 
therapy groups, had a significant improvement in mean NPC and PFV at near. The study 
defined a “successful outcome” with a CISS <16, an NPC of less than 6 cm, and a PFV 
greater than 15Δ and passing Sheard’s criterion. The study defined an “improved outcome” 
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with a CISS <16 or a 10-point decrease, and at least one of the following: NPC of less than 
6 cm, NPC improvement of more than 4 cm, PFV greater than 15Δ, or an increase in PFV 
of more than 10Δ. The therapy groups had significantly different amounts of group 
members experience “successful or improved outcomes” with the OBVAT, HBPP, 
HBCVAT+, and OBPT, experiencing 73%, 43%, 33%, and 35% respectively [43][44]. 
This study attempts to build on the CITT findings by using latency, time to peak 
velocity, peak velocity, and final amplitude to evaluate OBVAT and OBPT in addition to 
the clinical measures above.  
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CHAPTER 2 
METHODS 
 
2.1 Participants and Screening 
This study had a total of 50 participants aged between 18 to 35 years (inclusive), with 
symptomatic convergence insufficiency. Symptomatic convergence insufficiency was 
defined by 4 major criteria. First, a symptomatic score on the CISS (average score of 21 or 
higher). Second, a near point of convergence greater than or equal to 6 cm. Third, an 
exophoria at near greater than far by at least 4 prism diopters (Δ). Fourth, an insufficient 
positive fusional vergence defined as failing Sheard’s criterion (30) or a positive fusional 
vergence of less than 15Δ base-out. Participants were required to have 20/25 visual acuity 
or better (with refractive correction if needed), no history of previous vision therapy, stable 
general health, intact cognitive function, and no other neurological conditions. A complete 
list of eligibility and exclusion criteria is included in Table 2.1. An informed consent was 
signed by all participants in accordance with the Declaration of Helsinki and approved by 
the NJIT review Board. Participants were randomly assigned to a therapy group, either 
OBVAT or OBPT using the CONSORT Agreement [45]. They were kept naïve to which 
group they were assigned to throughout the study. 
 Participants underwent an examination to determine eligibility. Clinical testing and 
measurements were taken in the following order: visual acuity, auto-refraction, stereopsis 
(Randot Stereotest), CISS, cover/uncover (unilateral cover) test at distance and near, 
alternate cover test with prism neutralization at distance and near, negative fusional 
vergence (blue, break, and recovery) at near, positive fusional vergence (blur, break, and 
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recover) at near, near point of convergence break and recovery, vergence facility at distance 
and near, push-up accommodative amplitude, accommodative facility (right eye only) with 
+2.00/-2.00 lenses.  
The clinical outcome measures used were the CISS score, NPC, and PFV.  The CISS 
was measured before and after all testing. An example of the CISS is shown in Figure A1. 
The NPC was measured with the Near Point Rule (Gulden Ophthalmics, Elkins Park, PA) 
with a printed Gulden fixation target consisting of a single column of 20/30 letters at 40 
cm. The PFV was measured at near with a horizontal prism bar (Gulden B-16 horizontal 
prism bar levels from 1 Δ to 45 Δ, Gulden Ophthalmics, Elkins Park, PA) while the patient 
fixated a hand-held fixation target (Gulden Fixation Stick # 15302) with a single column 
of letters of 20/30 equivalent. The group values are summarized below in Table 2.2. All 
participant screening and clinical measures were performed by a licensed optometrist. 
Table 2.1 Table of Eligibility and Exclusion Criteria for CI Participants  
Eligibility Criteria for Convergence Insufficiency (CI) Participants 
Age 18 to 35 years 
Best-corrected visual acuity of 20/25 or better in both eyes at distance 
Convergence Insufficiency Symptom Survey score ≥21 
Exodeviation at near at least 4 greater than at far 
Receded near point of convergence of ≥6 cm break 
Insufficient positive fusional convergence (i.e., failing Sheard’s criterion or ≤15 blur or 
break) on positive fusional vergence testing using a prism bar) 
Random dot stereopsis appreciation of 500 seconds of arc or better 
Wearing appropriate refractive correction (spectacles or contact lenses) for at least 2 
weeks  
Informed consent and willingness to participate in the study and be randomized 
 
Exclusion Criteria for CI Participants 
Constant strabismus at distance  
Vertical heterophoria ≥2∆ at distance or near 
≥2 lines interocular difference in best-corrected visual acuity 
Accommodative amplitude <5 D in either eye as measured by Donder’s push-up method 
Manifest or latent nystagmus  
History of strabismus surgery or refractive surgery 
History of head trauma or known disease of the brain 
Diseases known to affect accommodation, vergence, or ocular motility  
Inability to comprehend and/or perform any study-related test 
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Table 2.2 Table of Participant’s Averages for Clinical Values 
 Age (years) Gender CISS NPC (cm) PFV (∆) 
OBVAT 
Participants 
21.08 ± 3.60 14M, 11F 33.96 ± 8.97 10.52 ± 3.67 12.24 ± 3.18 
OBPT 
Participants 
20.64 ± 3.06 11M, 14F 35.12 ± 6.13 10.36 ± 3.32 12.84 ± 4.51 
 
 
2.2 Experimental Setup 
2.2.1 Instrumentation 
The ISCAN RK-826PCI binocular tracking system (Burlington, MA) was used to record 
eye movements. The setup of the system is shown in Figure 2.1. The system used a central 
infrared emitter to envelop both eyes with light, then an infrared camera on either side of 
the face is used to record each eye. The infrared light was emitted at a wavelength of 950 
nm and power of 1.2 mW/cm2. This was considerably lower than the ANSI Z136 standard 
safety limit of 10 mW/cm2. The pupils absorb the light, while the rest of the eyes reflect 
the light. The ISCAN software is used to locate the centroid of each pupil. Thus, the device 
is able to record pupil location and diameter, horizontal and vertical eye movements, and 
the movements of the reflection from the corneal surface. The manufacturer reports an 
accuracy of 0.3 degrees over a ±20 degree horizontal and vertical range. A 12-bit digital 
acquisition (DAQ) card (National Instruments 604 E series, Austin, TX) digitized the eye 
movement data recorded from the ISCAN instrumentation with a sampling frequency of 
500 Hz. Two monitors and partially reflecting mirrors were used to present stimuli to the 
left and right eyes independently [46]. In totality this setup is referred to as a haploscope. 
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Figure 2.1 Haploscope experimental setup. The setup presents stimuli to the participant 
and collects eye movements. 
 
2.2.2 Software, Stimuli, and Data Collection 
VisualEyes, a custom LabVIEWTM (National Instruments, Austin, TX) program was used 
to control the stimuli presentation and data collection from the instrumentation. Digitized 
eye movement data was collected from the DAQ. Visual stimuli were generated on each 
monitor, that are then reflected to each of the participant’s eyes using the mirrors. The 
visual stimuli are presented to the left and right eyes separately [46]. This simulates a 
symmetrical disparity vergence stimulus along the participant’s midline. Accommodation 
is kept constant in this experiment by keeping the total distance from the stimuli to the eyes 
(focal length) to 40 cm (2.5D). The stimuli presented to the participant is a Gabor patch as 
seen in Figure 2.2. The Gabor patch is a low spatial frequency cue, meaning it has soft 
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edges with a slightly blurry look. It was held constant at a 2-degree eccentricity for height 
and width in a darkened room [47]. The Gabor patch kept at a constant distance and size 
was used to reduce blur and proximal cues [47]. The constant and reduced accommodative 
and proximal cues allowed this study to focus on examining the effects of disparity 
vergence. 
 
Figure 2.2 Gabor Patch. This image is used as the stimuli for the study. 
Source: [48] 
 
 
2.3 Experimental Procedure 
2.3.1 Assessment Procedure 
An assessment to determine changes in the vergence ocular motor system was created. 
Participants performed the assessment before and after the therapy procedure. The 
assessment was designed to be different from the therapy procedure to reduce possible 
procedure learning. Additionally, procedural learning was reduced due to the large time 
between assessments. The assessment procedure was standard for all participants and did 
not account for the individual’s phoria level. 
 The assessment consisted of three sections: FAR, NEAR, and SACCADES. The 
FAR and NEAR sections are meant to simulate focusing on an object distant and close to 
a subject respectively. Before and after each section, a calibration was performed, then 
stimuli were presented, and eye movements were captured. A short break could be given 
to participants in-between sections. The calibration consisted of a 6-point monocular 
calibration in which 3 points were presented and recorded per eye, covering the range of 
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visual stimuli presented. There were three types of movements: disparity steps, 
disappearing steps, and saccades. Disparity steps and disappearing steps have vergence 
stimuli, where the stimuli on each screen move in opposite directions. Disparity steps begin 
at a certain position and instantaneously change to a different position. A disappearing step 
is the same as a disparity step, but the stimuli disappear 0.100 seconds after moving. 
Saccades are similar to disparity steps, however the stimuli presented to each eye move in 
the same direction. This was a version movement rather than a vergence movement. These 
movement types are shown in Figure 2.3. The order of movements was the same for all 
participants. However, this standard order was created in a randomized order to decrease 
participant learning and prediction and inhibit anticipatory movements. A complete list of 
movements is given in Table 2.3.  
 
 
 
Figure 2.3 Diagrams of different movement types used as stimuli.  
C
h
an
ge
 in
 V
er
ge
n
ce
 D
em
an
d
 
Initial Position 
Initial Position 
Final Position 
Final Position 
Divergence 
Le
ft
 E
ye
 
R
ig
h
t 
Ey
e
 
Initial Position 
Final Position 
Initial Position 
Final Position 
Le
ft
 E
ye
 
R
ig
h
t 
Ey
e
 
Convergence 
Disparity 
Step 
Disappearing 
Step 
Initial Position 
Initial Position 
Final Position 
Final Position 
Le
ft
 E
ye
 
R
ig
h
t 
Ey
e
 
Leftward Saccades 
Initial Position 
Initial Position 
Final Position 
Final Position 
Le
ft
 E
ye
 
R
ig
h
t 
Ey
e
 
Rightward Saccades 
Saccades 
Vergence Version 
17 
Table 2.3 Table of Movement Types 
Section Movement Description 
Analysis 
Group 
FAR 
CON48 Convergence, disparity step, from 4 to 8 degrees CON4 
CON26 Convergence, disparity step, from 2 to 6 degrees CON4 
CON28 Convergence, disparity step, from 2 to 8 degrees CON6 
DIV82 Divergence, disparity step, from 8 to 2 degrees DIV6 
DIV62 Divergence, disparity step, from 6 to 2 degrees DIV4 
DIV84 Divergence, disparity step, from 8 to 4 degrees DIV4 
DS_DIV84 Divergence, disappearing step, from 8 to 4 degrees DSDIV4 
DS_DIV82 Divergence, disappearing step, from 8 to 2 degrees DSDIV6 
DS_DIV62 Divergence, disappearing step, from 6 to 2 degrees DSDIV4 
DS_CON48 Convergence, disappearing step, from 4 to 8 degrees DSCON4 
DS_CON26 Convergence, disappearing step, from 2 to 6 degrees DSCON4 
DS_CON28 Convergence, disappearing step, from 2 to 8 degrees DSCON6 
NEAR 
CON812 Convergence, disparity step, from 8 to 12 degrees CON4 
CON610 Convergence, disparity step, from 6 to 10 degrees CON4 
CON612 Convergence, disparity step, from 6 to 12 degrees CON6 
DIV128 Divergence, disparity step, from 12 to 8 degrees DIV6 
DIV106 Divergence, disparity step, from 10 to 6 degrees DIV4 
DIV126 Divergence, disparity step, from 12 to 6 degrees DIV4 
DS_DIV126 Divergence, disappearing step, from 12 to 6 degrees DSDIV6 
DS_DIV106 Divergence, disappearing step, from 10 to 6 degrees DSDIV4 
DS_DIV128 Divergence, disappearing step, from 12 to 8 degrees DSDIV4 
DS_CON612 Convergence, disappearing step, from 6 to 12 degrees DSCON6 
DS_CON610 Convergence, disappearing step, from 6 to 10 degrees DSCON4 
DS_CON812 Convergence, disappearing step, from 8 to 12 degrees DSCON4 
SACCADES 
M2R5 Saccade, middle to right, 5 degrees SAC5 
R2M5 Saccade, right to middle, 5 degrees SAC5 
M2L5 Saccade, middle to left, 5 degrees SAC5 
L2M5 Saccade, left to middle, 5 degrees SAC5 
M2R10 Saccade, middle to right, 10 degrees SAC10 
R2M10 Saccade, right to middle, 10 degrees SAC10 
M2L10 Saccade, middle to left, 10 degrees SAC10 
L2M10 Saccade, left to middle, 10 degrees SAC10 
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2.3.2 Therapy Procedure 
All participants took part in a total of 12 hours of office-based therapy and approximately 
3 hours of home-based reinforcement therapy. Office-based therapy occurred once to twice 
per week, for about one hour per session, for 6 to 12 weeks. Home-based reinforcement 
therapy occurred three times per week for about 10 minutes per session on days without 
office-based therapy. Participants were randomly assigned to two therapy groups and 
participated in either OBPT or OBVAT. These therapies are identical to those performed 
in the CITT study [42][46][47]. The OBPT therapy was not designed to improve vergence 
or accommodation, but instead encourage the participants believe they were receiving the 
correct therapy. The OBVAT therapy was designed to improve both disparity vergence and 
accommodation. The OBPT therapy consisted of a combination of techniques that changed 
weekly: Necker Cube, HTS Placebo Accommodation and Vergence, Monocular Brock 
String, Visual Closure, Double Maddox rod, etc. Typically, these techniques are used to 
improve monocular inputs, eye focusing, ability to detect targets, visual response speed, 
eye teaming skills, and visual processing skills. The OBPT therapy schedule is shown in 
Figure 2.4. The OBVAT therapy had three phases. Phase one included techniques to 
improve gross convergence, positive fusional vergence, and monocular accommodative 
therapy. Phase two included techniques to improve ramp fusional vergence and monocular 
accommodative therapy. Phase three included techniques to improve jump fusional 
vergence and binocular accommodative therapy. Techniques included were Vectograms, 
Brock String, Barrell Card, Loose Lens Accommodative Rock, Letter Chart 
Accommodative Rock, Life Saver Cards, Eccentric Circles, HTS, etc. The OBVAT therapy 
schedule is shown in Figure 2.5. 
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Figure 2.4a This is the first part of the OBPT therapy schedule. 
Source: [49] 
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Figure 2.4b This is the second part of the OBPT therapy schedule. 
Source: [49] 
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Figure 2.4c This is the third part of the OBPT therapy schedule. 
Source: [49] 
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Figure 2.5 This is the OBVAT therapy schedule. 
Source: [50] 
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2.4 Data Analysis 
2.4.1 Data Processing 
After eye movement data collection during the assessment procedure, the data was 
imported into MATLAB where it was analyzed. To calculate the vergence movement 
between the eyes, the raw right eye positional data was subtracted from the left eye 
positional data. For the FAR section the 1°, 3°, and 5° monocular calibrations corresponded 
to the 2°, 6°, and 10° binocular vergence angle demand. For the NEAR section the 4°, 5°, 
and 6° monocular calibrations corresponded to the 8°, 10°, and 12° binocular vergence 
angle demand. For the SACCADES section the 10° into left visual field, 0° on midline, 
and 10° into right visual field monocular calibrations corresponded to the 10° left, 0°, 10° 
right, binocular version angle demand. Eye movements that could not be analyzed due to 
saccade, blinks, etc. were removed. Outliers were removed (2 standard deviations away 
from the mean). Finally, similar movement types were grouped together for analysis. 
2.4.2 Measures and Metrics 
Four metrics were measured from the vergence eye movements: latency, time to peak 
velocity, peak velocity, and final amplitude. Latency is the amount of time from the stimuli 
to the start of the vergence eye movement. Time to peak velocity is the amount of time 
from the stimuli to the point at which the maximum velocity of the vergence eye movement. 
Peak velocity is the largest velocity during the vergence eye movement. The final 
amplitude is the final position of the eyes at the end of the vergence eye movement. Figure 
2.6 A shows the position over time plot as well as the latency and final amplitude. Figure 
2.6 B shows the velocity over time plot as well as the peak velocity and time to peak 
velocity. These values measured and compared before and after therapy, with therapy type 
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as OBPT or OBVAT, and between genders using a mixed ANOVA. After the mixed 
ANOVA, t-tests were performed. 
 
Figure 2.6 This figure shows a 4-degree convergence disparity step eye movement.  
Figure A is a Position over Time graph, and Figure B is a Velocity over Time graph of the 
same movement. Figure A shows the measured Latency and Final Amplitude. Figure B 
shows the measured Time to Peak Velocity and Peak Velocity.  
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CHAPTER 3 
RESULTS 
 
3.1 Clinical Results 
Table 3.1 Table of OBVAT Participant’s Clinical Values 
Participant 
ID 
Participant 
type 
Therapy 
type 
Age 
(years) 
Sex 
CISS Score NPC (cm) PFV (∆) 
Before After Before After Before After 
NIH032 CI Active 19 M 34 28 6.5 3 10 20 
NIH035 CI Active 18 M 36 18 7.5 3 12 30 
NIH042 CI Active 18 F 25 23 13.5 7.5 14 16 
NIH055 CI Active 18 M 29 31 9 4 10 45 
NIH081 CI Active 19 M 30 15 13.5 4 6 50 
NIH088 CI Active 24 M 25 19 8 5 10 45 
NIH103 CI Active 18 F 33 29 7.5 4 18 35 
NIH107 CI Active 19 M 42 40 10.5 8 12 16 
NIH110 CI Active 25 M 37 21 8 3.5 12 45 
NIH113 CI Active 19 F 37 31 17 6 16 35 
NIH118 CI Active 21 M 30 16 21 3 6 50 
NIH121 CI Active 18 F 34 33 7 5 12 30 
NIH125 CI Active 21 M 32 24 9 8 12 25 
NIH129 CI Active 19 M 34 19 10 2.5 8 45 
NIH138 CI Active 25 F 21 24 7.5 5 12 45 
NIH154 CI Active 20 M 57 14 13 4.5 16 45 
NIH164 CI Active 22 F 23 16 14 5 10 25 
NIH165 CI Active 18 F 22 7 12 3 12 45 
NIH167 CI Active 19 F 47 18 9 3.5 14 30 
NIH168 CI Active 18 M 45 15 11 3 12 35 
NIH169 CI Active 25 M 47 34 9 5 14 30 
NIH173 CI Active 31 F 23 20 8.5 6.5 16 16 
NIH176 CI Active 25 F 42 18 8.5 3 18 50 
NIH178 CI Active 28 F 30 10 6.5 4 14 18 
NIH187 CI Active 20 M 34 18 16 4.5 10 35 
Averages 
 33.96 
±8.97 
21.64 
±7.99  
 10.52 
±3.67 
4.54 
±1.60  
12.24 
±3.18 
34.44 
±11.66 
Paired T Test (Within Participant) Significance 
t=5.589 
df=24 
p<0.001 
 t=7.644 
df=24 
p<0.001 
 t=-8.602 
df=24 
p<0.001 
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Table 3.2 Table of OBPT Participant’s Clinical Values 
Participant 
ID 
Participant 
type 
Therapy 
type 
Age 
(years) 
Sex 
CISS Score NPC (cm) PFV (∆) 
Before After Before After Before After 
NIH038 CI Placebo 26 F 26 23 13.5 10 25 18 
NIH046 CI Placebo 19 M 40 16 12 4.5 14 45 
NIH105 CI Placebo 18 F 42 20 14 6.5 16 25 
NIH108 CI Placebo 18 F 33 22 10 9 18 25 
NIH111 CI Placebo 23 F 40 26 8 4.5 8 25 
NIH112 CI Placebo 21 M 32 23 20 3 4 40 
NIH115 CI Placebo 22 F 42 38 8.5 4 8 30 
NIH117 CI Placebo 32 M 43 13 7 5.5 16 18 
NIH119 CI Placebo 19 F 43 24 7 7 14 25 
NIH120 CI Placebo 19 M 36 14 10 9.5 12 18 
NIH122 CI Placebo 20 F 36 44 8 2 16 25 
NIH123 CI Placebo 20 F 34 26 9 7.5 12 12 
NIH124 CI Placebo 19 F 30 29 9 8 14 20 
NIH127 CI Placebo 18 F 46 18 15 8 14 16 
NIH133 CI Placebo 18 F 31 31 12 9 10 14 
NIH137 CI Placebo 21 F 24 35 8 3.5 14 35 
NIH140 CI Placebo 18 M 35 20 12 8 10 16 
NIH156 CI Placebo 25 F 26 23 6.5 5 18 18 
NIH162 CI Placebo 28 M 40 22 14 3.5 16 14 
NIH166 CI Placebo 18 M 26 32 8 6.5 6 4 
NIH170 CI Placebo 20 M 38 41 14 10.5 14 16 
NIH171 CI Placebo 18 M 37 18 8 5 8 14 
NIH172 CI Placebo 18 M 31 30 11 9 12 16 
NIH186 CI Placebo 19 F 37 23 7.5 7 14 20 
NIH191 CI Placebo 19 M 30 23 7 5.5 8 25 
Averages 
 35.12 
±6.13 
25.36 
±8.02  
10.36 
±3.32 
6.46 
2.38 
12.84 
4.51 
21.36 
±9.04 
Paired T Test (Within Participant) Significance 
 t=4.300 
df=24 
p<0.001 
 t=5.139 
df=24 
p<0.001 
 t=-4.126 
df=24 
p<0.001 
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Table 3.3 Table of Unpaired T-Tests Between Therapy Groups 
Independent Samples Test 
Clinical 
Measure 
Time t df p 
CISS 
Before -.534 48 .596 
After -1.643 48 .107 
NPC 
Before .162 48 .872 
After -3.351 48 .002 
PFV 
Before -.544 48 .589 
After 4.432 48 .000 
 
 
Table 3.1 has the clinical values for participants in the active therapy group. The active 
therapy CI participants have average values of 21.64±7.99 for CISS, 4.54±1.60 cm for 
NPC, and 34.44±11.66 Δ for PFV. Table 3.2 has the clinical values for participants in the 
placebo therapy group. The placebo therapy CI participants have average values of 
25.36±8.02 for CISS, 6.46±2.38 cm for NPC, and 21.36±9.04 Δ for PFV. Values for CISS, 
NPC, and PFV all showed statistically significant change (p<0.001). Table 3.3 has the 
results of unpaired t-tests for clinical measures between OBPT and OBVAT groups. Before 
therapy, none of the clinical measures have any statistical difference between groups. After 
therapy the between therapy PFV values have a difference with statistical significance of 
p<0.001, NPC have a statistical significance of p<0.01, and the CISS values exhibit a trend 
p=0.1. 
 
3.2 Latency Results 
Figures 3.1 to 3.3 show the combined movement results for latency with statistical 
significance shown. Table B1 shows the results from the Mixed ANOVA. Gender 
differences were not significant for any of the latency results. Movements with statistical 
significance were CON4, CON6, DIV6, DSCON4, DSDIV6, and SAC10. Table C1 shows 
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the unpaired t-test results. Unpaired t-tests with statistical significance were not identical 
to the results from the Mixed ANOVA. Tables D1 and D2 show the paired t-test results. 
Results with significance from both the Mixed ANOVA and paired t-tests were for CON4 
before and after OBPT, and SAC10 before and after OBVAT. 
 
Figure 3.1 Bar plots showing the means and standard deviations of latency for convergence 
disparity and disappearing steps for both Active (OBVAT) and Placebo (OBPT) therapy 
groups. 
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Figure 3.2 Bar plots showing the means and standard deviations of latency for divergence 
disparity and disappearing steps for both Active (OBVAT) and Placebo (OBPT) therapy 
groups. 
 
 
 
Figure 3.3 Bar plots showing the means and standard deviations of latency for saccades 
for both Active (OBVAT) and Placebo (OBPT) therapy groups. 
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3.3 Time to Peak Velocity Results 
Figures 3.4 to 3.6 show the combined movement results for Time to Peak Velocity with 
statistical significance shown. Table B2 shows the results from the Mixed ANOVA. 
Gender differences were not significant for any of the time to peak velocity results. 
Movements with statistical significance were CON4, CON6, DSDIV4, SAC5, and SAC10. 
Table C2 shows the unpaired t-test results. Results with significance from both the Mixed 
ANOVA and unpaired t-tests were only DSDIV4 post therapy between OBPT and 
OBVAT. Tables D3 and D4 show the paired t-test results. Results with significance from 
both the Mixed ANOVA and paired t-tests were for CON4 and DSDIV4 before and after 
OBPT therapy, and CON4, CON6, SAC5, and SAC10 before and after OBVAT therapy. 
  
Figure 3.4 Bar plots showing the means and standard deviations of time to peak velocity 
for convergence disparity and disappearing steps for both Active (OBVAT) and Placebo 
(OBPT) therapy groups. 
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Figure 3.5 Bar plots showing the means and standard deviations of time to peak velocity 
for divergence disparity and disappearing steps for both Active (OBVAT) and Placebo 
(OBPT) therapy groups. 
 
 
  
Figure 3.6 Bar plots showing the means and standard deviations of time to peak velocity 
for saccades for both Active (OBVAT) and Placebo (OBPT) therapy groups. 
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3.4 Peak Velocity Results 
Figures 3.7 to 3.9 show the combined movement results for Peak Velocity with statistical 
significance shown. Table B3 shows the results from the Mixed ANOVA. Gender 
differences were not significant for any of the peak velocity results. Movements with 
statistical significance were CON4, CON6, DIV4, DIV6, and DSDIV4. Table C3 shows 
the unpaired t-test results. Unpaired t-tests with statistical significance were not identical 
to the results from the Mixed ANOVA. Tables D5 and D6 show the paired t-test results. 
Results with significance from both the Mixed ANOVA and paired t-tests were for CON4, 
DIV4, and DSDIV4 before and after OBPT therapy, and CON4, CON6, DIV4, and DIV6 
before and after OBVAT therapy. 
 
Figure 3.7 Bar plots showing the means and standard deviations of peak velocity for 
convergence disparity and disappearing steps for both Active (OBVAT) and Placebo 
(OBPT) therapy groups. 
 
 
0
5
10
15
20
25
30
35
40
4° CON 6° CON 4°
DSCON
6°
DSCON
4° CON 6° CON 4°
DSCON
6°
DSCON
Active Placebo
Convergence Peak Velocity
Before After
** ** 
** 
*   = p<0.05 
** = p<0.01 
33 
  
Figure 3.8 Bar plots showing the means and standard deviations of peak velocity for 
divergence disparity and disappearing steps for both Active (OBVAT) and Placebo 
(OBPT) therapy groups. 
 
 
  
Figure 3.9 Bar plots showing the means and standard deviations of peak velocity for 
saccades for both Active (OBVAT) and Placebo (OBPT) therapy groups. 
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3.5 Final Amplitude Results 
The target disappears before a final amplitude can be reach during disappearing steps. 
Thus, disappearing step results for final amplitude are not shown due to a lack of meaning. 
Figures 3.10 to 3.11 show the combined movement results for Final Amplitude with 
statistical significance shown. Table B4 shows the results from the Mixed ANOVA. There 
were no significant values from the Mixed ANOVA, thus there are no t-test values that 
showed significance with the Mixed ANOVA results. 
 
Figure 3.10 Bar plots showing the means and standard deviations of final amplitude for 
convergence disparity and disappearing steps for both Active (OBVAT) and Placebo 
(OBPT) therapy groups. 
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Figure 3.11 Bar plots showing the means and standard deviations of final amplitude for 
divergence disparity and disappearing steps for both Active (OBVAT) and Placebo 
(OBPT) therapy groups. 
 
 
  
Figure 3.12 Bar plots showing the means and standard deviations of final amplitude for 
saccades for both Active (OBVAT) and Placebo (OBPT) therapy groups. 
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CHAPTER 4 
DISCUSSION AND CONCLUSIONS 
 
4.1 Discussion 
The clinical values of CISS, NPC, and PFV are statistically different after therapy 
regardless of therapy type. Further, although the CISS, NPC, and PFV have no statistical 
difference between the two groups (OBPT and OBVAT) before therapy, after therapy there 
is a statistical difference between both of the following clinical parameters: NPC and PFV. 
The improvement in clinical parameters supports that the participants improved after 
therapy, and OBVAT improved patient outcomes significantly greater than OBPT. These 
results agree with previous studies [42]. It can also be noted that average values for CISS, 
NPC, and PFV were well above the symptomatic cutoff values for both OBVAT and OBPT 
groups before therapy. After OBVAT the average CISS changed from 33.96±8.97 with a 
range of 21 to 57, to 21.64±7.00 with a range of 7 to 40, which is remarkably close to the 
21 threshold for symptomatic CI diagnosis. Further, the average NPC and PFV values 
changed from 10.54±3.67 cm with a range of 6.5 cm to 21cm and 12.24±3.18Δ with a 
range of 6Δ to 18Δ to 4.54±1.60cm with a range of 2.5cm to 8cm and 34.44±11.66Δ with 
a range of 16Δ to 50Δ. Both of the average values for NPC and PFV changed from the 
symptomatic CI diagnosis threshold to non-symptomatic. The NPC improved to below 
6cm and the PFV improved to above 15Δ. However, none of the average clinical measures 
(CISS, NPC, and PFV) changed to below the symptomatic CI threshold after therapy for 
OBPT. Clinical results were similar to other randomized clinical trials [42]. This is the first 
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properly powered randomized clinical trial to include eye movement metrics before and 
after vision therapy. 
 The Dual Mode Theory of disparity vergence has two components the 
preprogrammed FIC, and feedback controlled FSC [18]-[23]. The FIC is believed to be 
generated by the “velocity-encoding” burst cells near the oculomotor nucleus in the 
midbrain. The FSC mimics the “position-encoding” tonic cells located in the midbrain. The 
burst and tonics cells are distinct. The peak velocity metric is used to assess the FIC, and 
the final amplitude metric is used to assess the FSC. 
 The final amplitude results have no statistically significant difference before or after 
any therapy or between therapy groups. The lack of change in final amplitude suggests that 
the FSC is not as strongly affected by therapy as the FIC. The saccadic movements were 
included as a control measure since CI subjects have disfunction in vergence movements, 
not saccades. The lack of statically significant change in the final amplitude of the saccades, 
as well as the relative accuracy and precision of these movements to the expected outcomes 
(5 and 10 degrees of change) demonstrates that eye movements were properly calibrated. 
It should be noted that if a participant is unable to complete an eye movement, it is not 
analyzed. The final amplitude results show a general trend that subjects generally have a 
binary response, either the participants make a successful eye movement to achieve fusion 
of the image, or they fail catastrophically. It is extremely rare for a participant to have an 
eye movement that fails to achieve fusion of the image and stabilizes just above or below 
the correct fusion angle. If a participant is unable to achieve fusion, they tend to lose fusion. 
 The peak velocity results showed general trends of increased peak velocity after 
therapy. The OBVAT group has statistically significant (p<0.01) changes after therapy for 
38 
4° convergence and divergence, and 6° convergence and divergence steps. The OBPT 
group had statistically significant changes after therapy for 4° convergence (p<0.01), and 
4° divergence and disappearing divergence (p<0.05) steps. These results show the peak 
velocity of participants statistically improved after therapy. The change in peak velocity 
confirms the FIC of the Dual Mode Theory of disparity vergence is changing due to both 
therapies. However, OBVAT showed more change than OBPT, both in the number of 
movements with statistical difference, and the degree of statistical significance for those 
movements. These results agree with the clinical measures which also showed a 
statistically significant change in both therapy groups, but with a larger change in the 
OBVAT over OBPT group.  
 The latency results showed general trends of decreasing after therapy –faster 
reaction time. The 4° convergence for OBPT and 10° saccade for OBVAT were the only 
movements with statically significant changes after therapy. In general, these results were 
similar for OBPT and OBVAT. The time to peak velocity showed similar trends to latency 
in which it generally decreased after therapy. The 4° and 6° convergence and 5° and 10° 
saccades for the OBVAT group changed significantly after therapy. The 4° convergence 
and divergence steps for the OBPT group changed significantly after therapy. These results 
show decreases in both therapy groups, with the OBVAT group showing more change than 
OBPT, both in the number of movements with statistical difference, and the degree of 
statistical significance for those movements. Generally, latency and time to peak velocity 
are correlated values. The latency can be viewed as the reaction time. The time to peak 
velocity can be viewed as a measure of the acceleration of the eye. Thus, both therapy 
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groups improve the reaction time to a relatively similar degree. However, the OBVAT 
therapy group improves the acceleration of the eye more significantly than the OBPT.  
 The latency and time to peak velocity results agree with previous studies showing 
improvements in saccades due to vergence rehabilitation [51],[52]. Other studies have gone 
as far as to suggest saccade-vergence interactions in human which could be the cause for 
improvements in saccades from vergence therapy [53]. Further it has been shown that large 
amounts of visual stimuli such as in videogames and training can speed up reaction time 
[54]. 
 The results objective eye movement measures were generally the same for 
convergence and divergence movements. The latency, time to peak, and final amplitude 
results all were about the same values and showed the same trends when comparing the 
same type of movements (CON4 to DIV4, DSCON6 to DSDIV6, etc.). Generally, the peak 
velocity for convergence movements was higher than divergence movements, but the 
changes after therapy were approximately the same. Behavioral plots are provided in 
APPENDIX E for reference. 
 
4.1 Conclusions and Future Work 
This study showed that OBVAT leads to statistically significant improvements in the 
disparity vergence oculomotor system. Further, these improvements are greater for 
OBVAT compared to OBPT. These improvements can be seen both in clinical measures, 
and in objective measures of eye movements. The results from the clinical and objective 
measures agree with one another. The eye movement measures of final amplitude and peak 
velocity show that the different components of the Dual-Mode Model are trained during 
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therapy. The FIC is trained, while the final amplitude does not show a statistically 
significant change. This study looks at CI participants. These results can be used to 
compare against similar results to binocularly normal controls. 
 A limitation of the current study methodology is that it does not take into account 
the eye movements that fail. Different measures could be developed which account for and 
measure these failures. For instance, a percentage of successful movements could be 
measured to show if participants have more successful movements, and thus less failures, 
after therapy. It could also be possible to develop a method of averaging similar movement 
types together, smoothing the results, and then taking movement measures from the 
averaged eye movement wave. This metric would not give accurate absolute measures of 
the eye movements, but would give relative measures of the eye movements which could 
be compared before and after therapy. This metric would have the benefit of accounting 
for failed movements, as well as, the scattering and imprecision of similar movements. 
Increased precision and reliability of movements would cause sharper averaged eye 
movements. 
 An asymmetry analysis between the left and right eye movement response would 
also yield insight into the differences between the dominance of one eye compared to 
another. Prior pilot studies support that CI eye movements are more asymmetrical 
compared to binocularly normal controls and that asymmetry improves post therapy 
[55],[56]. 
 Overall the results of this study support the effectiveness of office-based vergence 
and accommodation therapy for people with CI.  Participant reported symptoms, clinical 
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measures, and objective eye movement measures all improve in people with CI who 
undergo OBVAT.  
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APPENDIX A 
CONVERGENCE INSUFFICIENCY SYMPTOM SURVEY (CISS) 
 
 
Figure A1 Convergence Insufficiency Symptom Survey (CISS).  
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APPENDIX B 
MIXED ANOVA 
 
Table B1 A table of statistical results from a Mixed ANOVA, showing the factor, error df, 
and significance between-factor (before vs after therapy), between-sex (M vs F), and 
between-therapy (OBPT vs OBVAT) for each movement’s Latency. The tests with 
statistical significance are highlighted in green. 
 
Latency 
    F Error df Sig 
CON4 
Factor 5.675b 44 0.0216 
Sex .196b 44 0.660134 
Therapy .030b 44 0.864347 
CON6 
Factor 9.394b 40 0.003889 
Sex 2.426b 40 0.127232 
Therapy .211b 40 0.648386 
DIV4 
Factor .494b 41 0.486177 
Sex 1.932b 41 0.172 
Therapy 3.024b 41 0.089549 
DIV6 
Factor 3.864b 38 0.056669 
Sex 2.359b 38 0.132828 
Therapy 4.308b 38 0.044747 
DSCON4 
Factor 6.632b 31 0.015011 
Sex 3.633b 31 0.06597 
Therapy .356b 31 0.555168 
DSCON6 
Factor 1.901b 29 0.17846 
Sex .812b 29 0.375038 
Therapy .190b 29 0.666321 
DSDIV4 
Factor 1.229b 39 0.274379 
Sex .905b 39 0.347306 
Therapy .193b 39 0.663226 
DSDIV6 
Factor .095b 34 0.760193 
Sex .393b 34 0.535048 
Therapy 4.385b 34 0.043784 
SAC5 
Factor 3.252b 47 0.077749 
Sex .010b 47 0.922647 
Therapy .587b 47 0.447248 
SAC10 
Factor 12.509b 47 0.000923 
Sex .972b 47 0.329183 
Therapy 2.614b 47 0.112629 
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Table B2 A table of statistical results from a Mixed ANOVA, showing the factor, error df, 
and significance between-factor (before vs after therapy), between-sex (M vs F), and 
between-therapy (OBPT vs OBVAT) for each movement’s Time to Peak Velocity. The 
tests with statistical significance are highlighted in green. 
 
Time to Peak Velocity 
    F Error df Sig 
CON4 
Factor 11.581b 44 0.00143 
Sex .195b 44 0.660785 
Therapy 2.976b 44 0.091535 
CON6 
Factor 15.834b 41 0.000275 
Sex 3.530b 41 0.067381 
Therapy 1.552b 41 0.219863 
DIV4 
Factor 1.516b 41 0.225287 
Sex .442b 41 0.509906 
Therapy .550b 41 0.462699 
DIV6 
Factor .508b 35 0.480717 
Sex .031b 35 0.862325 
Therapy .161b 35 0.690729 
DSCON4 
Factor 1.543b 31 0.223418 
Sex 1.408b 31 0.244422 
Therapy .002b 31 0.965297 
DSCON6 
Factor 1.976b 28 0.170809 
Sex 3.488b 28 0.072303 
Therapy .001b 28 0.972101 
DSDIV4 
Factor .951b 40 0.335244 
Sex .018b 40 0.894409 
Therapy 6.599b 40 0.014038 
DSDIV6 
Factor .206b 37 0.652667 
Sex .010b 37 0.921024 
Therapy 2.909b 37 0.096461 
SAC5 
Factor 5.946b 47 0.018584 
Sex .141b 47 0.709145 
Therapy .635b 47 0.429527 
SAC10 
Factor 13.881b 47 0.000522 
Sex 1.718b 47 0.196363 
Therapy 2.619b 47 0.11225 
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Table B3 A table of statistical results from a Mixed ANOVA, showing the factor, error df, 
and significance between-factor (before vs after therapy), between-sex (M vs F), and 
between-therapy (OBPT vs OBVAT) for each movement’s Peak Velocity. The tests with 
statistical significance are highlighted in green. 
 
Peak Velocity 
    F Error df Sig 
CON4 
Factor 9.402b 44 0.003699 
Sex .636b 44 0.429402 
Therapy 1.679b 44 0.201775 
CON6 
Factor 6.071b 41 0.018027 
Sex 1.810b 41 0.185843 
Therapy 4.129b 41 0.048668 
DIV4 
Factor 10.371b 42 0.002472 
Sex .000b 42 0.98866 
Therapy .280b 42 0.599457 
DIV6 
Factor 5.311b 38 0.026748 
Sex .840b 38 0.365075 
Therapy 2.782b 38 0.103573 
DSCON4 
Factor .146b 30 0.704808 
Sex 1.543b 30 0.223779 
Therapy .562b 30 0.459258 
DSCON6 
Factor 2.112b 28 0.157262 
Sex .018b 28 0.892817 
Therapy .028b 28 0.868184 
DSDIV4 
Factor 6.138b 39 0.017673 
Sex .230b 39 0.634299 
Therapy .631b 39 0.431823 
DSDIV6 
Factor .838b 35 0.366231 
Sex .151b 35 0.69968 
Therapy 1.451b 35 0.236491 
SAC5 
Factor 3.901b 47 0.054159 
Sex 2.521b 47 0.119073 
Therapy .032b 47 0.858595 
SAC10 
Factor 1.758b 47 0.191273 
Sex 1.305b 47 0.259031 
Therapy .581b 47 0.449561 
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Table B4 A table of statistical results from a Mixed ANOVA, showing the factor, error df, 
and significance between-factor (before vs after therapy), between-sex (M vs F), and 
between-therapy (OBPT vs OBVAT) for each movement’s Final Amplitude. The tests with 
statistical significance are highlighted in green. 
 
Final Amplitude 
    F Error df Sig 
CON4 
Factor 1.525b 43 0.223642 
Sex .174b 43 0.678233 
Therapy 3.301b 43 0.07621 
CON6 
Factor 1.205b 40 0.2788 
Sex .048b 40 0.827487 
Therapy 1.301b 40 0.260891 
DIV4 
Factor .554b 42 0.460906 
Sex .830b 42 0.367603 
Therapy .013b 42 0.911338 
DIV6 
Factor 2.113b 38 0.154266 
Sex .547b 38 0.463897 
Therapy 1.989b 38 0.166532 
DSCON4 
Factor 1.502b 30 0.22993 
Sex .092b 30 0.764235 
Therapy 1.705b 30 0.201597 
DSCON6 
Factor .016b 28 0.901609 
Sex .084b 28 0.77411 
Therapy .073b 28 0.788995 
DSDIV4 
Factor 1.575b 29 0.219491 
Sex .119b 29 0.732148 
Therapy .158b 29 0.693625 
DSDIV6 
Factor .426b 37 0.517828 
Sex .017b 37 0.898097 
Therapy .233b 37 0.632427 
SAC5 
Factor 1.217b 47 0.275639 
Sex .000b 47 0.984925 
Therapy 1.265b 47 0.266445 
SAC10 
Factor .448b 47 0.506726 
Sex .173b 47 0.679634 
Therapy 3.678b 47 0.061238 
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APPENDIX C 
UNPAIRED T-TESTS 
 
Table C1 A table of statistical results from an Unpaired T-Test between therapy groups 
(OBPT vs OBVAT) performed for all movements, before and after therapy for each 
movement’s Latency. The tests with statistical significance are highlighted in green. 
 
Latency 
 
Levene's Test 
for Equality of 
Variances 
t-test for Equality of Means 
F Sig. t df 
Sig. 
(2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
CON4PRE 
Equal 
variances 
assumed 
1.020 .318 -.823 45 .415 -.00676 .00821 -.02329 .00977 
Equal 
variances not 
assumed 
  -.831 38.524 .411 -.00676 .00813 -.02321 .00969 
CON4POST 
Equal 
variances 
assumed 
.938 .338 -1.179 47 .244 -.00528 .00448 -.01428 .00372 
Equal 
variances not 
assumed 
  -1.176 45.426 .246 -.00528 .00449 -.01432 .00376 
CON6PRE 
Equal 
variances 
assumed 
.229 .635 -.229 41 .820 -.00227 .00993 -.02233 .01778 
Equal 
variances not 
assumed 
  -.229 40.951 .820 -.00227 .00991 -.02229 .01774 
CON6POST 
Equal 
variances 
assumed 
.077 .782 -1.172 47 .247 -.00561 .00479 -.01525 .00402 
Equal 
variances not 
assumed 
  -1.171 46.790 .247 -.00561 .00479 -.01526 .00403 
DIV4PRE 
Equal 
variances 
assumed 
3.260 .078 2.248 43 .030 .01053 .00469 .00108 .01998 
Equal 
variances not 
assumed 
  2.262 40.930 .029 .01053 .00466 .00113 .01994 
DIV4POST 
Equal 
variances 
assumed 
3.387 .072 -.922 46 .361 -.00489 .00531 -.01557 .00579 
Equal 
variances not 
assumed 
  -.903 34.389 .373 -.00489 .00542 -.01591 .00612 
DIV6PRE 
Equal 
variances 
assumed 
4.596 .038 1.357 40 .182 .00881 .00649 -.00431 .02193 
Equal 
variances not 
assumed 
  1.384 36.445 .175 .00881 .00637 -.00409 .02171 
DIV6POST 
Equal 
variances 
assumed 
.145 .705 -1.192 44 .240 -.00595 .00499 -.01601 .00411 
Equal 
variances not 
assumed 
  -1.186 42.158 .242 -.00595 .00502 -.01608 .00418 
DSCON4PRE 
Equal 
variances 
assumed 
.022 .884 .460 34 .649 .00436 .00948 -.01491 .02362 
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Equal 
variances not 
assumed 
  .448 27.452 .657 .00436 .00972 -.01557 .02428 
DSCON4POST 
Equal 
variances 
assumed 
.597 .444 .375 40 .710 .00245 .00654 -.01077 .01567 
Equal 
variances not 
assumed 
  .369 34.616 .714 .00245 .00664 -.01103 .01593 
DSCON6PRE 
Equal 
variances 
assumed 
.009 .924 .707 32 .484 .00652 .00921 -.01225 .02528 
Equal 
variances not 
assumed 
  .681 22.504 .503 .00652 .00957 -.01331 .02635 
DSCON6POST 
Equal 
variances 
assumed 
.174 .679 -.635 38 .529 -.00500 .00788 -.02096 .01095 
Equal 
variances not 
assumed 
  -.633 34.302 .531 -.00500 .00790 -.02105 .01105 
DSDIV4PRE 
Equal 
variances 
assumed 
.130 .720 -.371 41 .713 -.00336 .00906 -.02167 .01494 
Equal 
variances not 
assumed 
  -.374 39.653 .711 -.00336 .00900 -.02157 .01484 
DSDIV4POST 
Equal 
variances 
assumed 
2.214 .144 -1.042 43 .303 -.00995 .00956 -.02923 .00932 
Equal 
variances not 
assumed 
  -1.007 34.074 .321 -.00995 .00988 -.03004 .01013 
DSDIV6PRE 
Equal 
variances 
assumed 
1.183 .284 2.147 37 .038 .01602 .00746 .00090 .03113 
Equal 
variances not 
assumed 
  2.042 26.635 .051 .01602 .00784 -.00008 .03212 
DSDIV6POST 
Equal 
variances 
assumed 
.027 .870 -.258 42 .797 -.00187 .00722 -.01643 .01270 
Equal 
variances not 
assumed 
  -.259 39.389 .797 -.00187 .00719 -.01641 .01268 
SAC5PRE 
Equal 
variances 
assumed 
.083 .774 -.088 48 .930 -.00059 .00667 -.01399 .01282 
Equal 
variances not 
assumed 
  -.088 47.964 .930 -.00059 .00667 -.01399 .01282 
SAC5POST 
Equal 
variances 
assumed 
.039 .845 .837 48 .406 .00400 .00477 -.00560 .01359 
Equal 
variances not 
assumed 
  .837 47.701 .406 .00400 .00477 -.00560 .01359 
SAC10PRE 
Equal 
variances 
assumed 
2.873 .097 -.094 48 .925 -.00058 .00614 -.01293 .01177 
Equal 
variances not 
assumed 
  -.094 43.000 .925 -.00058 .00614 -.01297 .01181 
SAC10POST 
Equal 
variances 
assumed 
1.299 .260 1.934 48 .059 .00755 .00391 -.00030 .01541 
Equal 
variances not 
assumed 
  1.934 45.382 .059 .00755 .00391 -.00031 .01542 
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Table C2 A table of statistical results from an Unpaired T-Test between therapy groups 
(OBPT vs OBVAT) performed for all movements, before and after therapy for each 
movement’s Time to Peak Velocity. The tests with statistical significance are highlighted 
in green. 
 
Time to Peak Velocity 
 
Levene's Test 
for Equality of 
Variances 
t-test for Equality of Means 
F Sig. t df 
Sig. 
(2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
CON4PRE 
Equal 
variances 
assumed 
3.866 .055 -1.750 45 .087 -.02615 .01495 -.05626 .00395 
Equal 
variances not 
assumed 
  -1.768 37.606 .085 -.02615 .01479 -.05611 .00380 
CON4POST 
Equal 
variances 
assumed 
2.306 .135 .549 48 .586 .00519 .00947 -.01385 .02424 
Equal 
variances not 
assumed 
  .549 44.361 .586 .00519 .00947 -.01389 .02428 
CON6PRE 
Equal 
variances 
assumed 
.524 .473 -1.880 42 .067 -.03298 .01754 -.06839 .00242 
Equal 
variances not 
assumed 
  -1.880 40.582 .067 -.03298 .01754 -.06842 .00246 
CON6POST 
Equal 
variances 
assumed 
.338 .564 -.948 47 .348 -.00993 .01048 -.03101 .01115 
Equal 
variances not 
assumed 
  -.945 45.184 .350 -.00993 .01051 -.03111 .01124 
DIV4PRE 
Equal 
variances 
assumed 
.001 .976 .269 42 .789 .00312 .01161 -.02031 .02655 
Equal 
variances not 
assumed 
  .269 42.000 .789 .00312 .01161 -.02031 .02655 
DIV4POST 
Equal 
variances 
assumed 
.339 .563 1.227 47 .226 .01111 .00906 -.00711 .02933 
Equal 
variances not 
assumed 
  1.226 46.673 .226 .01111 .00906 -.00713 .02935 
DIV6PRE 
Equal 
variances 
assumed 
1.543 .222 .431 39 .669 .00497 .01154 -.01836 .02830 
Equal 
variances not 
assumed 
  .433 38.103 .667 .00497 .01148 -.01826 .02820 
DIV6POST 
Equal 
variances 
assumed 
.173 .680 .007 43 .995 .00009 .01376 -.02766 .02785 
Equal 
variances not 
assumed 
  .007 42.786 .995 .00009 .01370 -.02754 .02773 
DSCON4PRE 
Equal 
variances 
assumed 
.089 .767 -.250 34 .804 -.00371 .01482 -.03383 .02641 
Equal 
variances not 
assumed 
  -.264 32.319 .794 -.00371 .01405 -.03230 .02489 
DSCON4POST 
Equal 
variances 
assumed 
1.201 .280 -.076 40 .939 -.00084 .01099 -.02306 .02137 
Equal 
variances not 
assumed 
  -.080 39.950 .937 -.00084 .01049 -.02204 .02036 
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DSCON6PRE 
Equal 
variances 
assumed 
.056 .814 -.821 32 .418 -.01318 .01605 -.04587 .01951 
Equal 
variances not 
assumed 
  -.865 29.602 .394 -.01318 .01525 -.04434 .01797 
DSCON6POST 
Equal 
variances 
assumed 
.512 .479 -.559 36 .580 -.00557 .00997 -.02579 .01465 
Equal 
variances not 
assumed 
  -.541 26.695 .593 -.00557 .01031 -.02674 .01559 
DSDIV4PRE 
Equal 
variances 
assumed 
.152 .699 -.583 42 .563 -.00762 .01306 -.03398 .01874 
Equal 
variances not 
assumed 
  -.581 40.025 .564 -.00762 .01311 -.03411 .01887 
DSDIV4POST 
Equal 
variances 
assumed 
1.412 .241 2.082 44 .043 .02546 .01223 .00082 .05010 
Equal 
variances not 
assumed 
  2.036 37.251 .049 .02546 .01250 .00013 .05079 
DSDIV6PRE 
Equal 
variances 
assumed 
.256 .616 .048 39 .962 .00073 .01518 -.02998 .03143 
Equal 
variances not 
assumed 
  .047 34.498 .963 .00073 .01539 -.03054 .03199 
DSDIV6POST 
Equal 
variances 
assumed 
1.627 .209 .561 43 .578 .00896 .01597 -.02325 .04117 
Equal 
variances not 
assumed 
  .542 34.047 .591 .00896 .01652 -.02461 .04252 
SAC5PRE 
Equal 
variances 
assumed 
.557 .459 .161 48 .873 .00123 .00761 -.01407 .01652 
Equal 
variances not 
assumed 
  .161 47.961 .873 .00123 .00761 -.01407 .01652 
SAC5POST 
Equal 
variances 
assumed 
1.490 .228 1.180 48 .244 .00674 .00571 -.00474 .01821 
Equal 
variances not 
assumed 
  1.180 44.451 .244 .00674 .00571 -.00477 .01824 
SAC10PRE 
Equal 
variances 
assumed 
2.878 .096 -.176 48 .861 -.00116 .00661 -.01444 .01212 
Equal 
variances not 
assumed 
  -.176 41.906 .861 -.00116 .00661 -.01449 .01217 
SAC10POST 
  
Equal 
variances 
assumed 
1.412 .241 1.648 48 .106 .00784 .00476 -.00173 .01740 
Equal 
variances not 
assumed 
  1.648 44.262 .106 .00784 .00476 -.00175 .01742 
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Table C3 A table of statistical results from an Unpaired T-Test between therapy groups 
(OBPT vs OBVAT) performed for all movements, before and after therapy for each 
movement’s Peak Velocity. The tests with statistical significance are highlighted in green. 
 
Peak Velocity 
 
Levene's Test 
for Equality of 
Variances 
t-test for Equality of Means 
F Sig. t df 
Sig. 
(2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
CON4PRE 
Equal 
variances 
assumed 
10.638 .002 1.402 45 .168 2.00453 1.42951 -.87466 4.88372 
Equal 
variances 
not assumed 
  1.421 33.785 .164 2.00453 1.41062 -.86287 4.87194 
CON4POST 
Equal 
variances 
assumed 
.090 .766 -.601 48 .551 -.95158 1.58360 -4.13563 2.23246 
Equal 
variances 
not assumed 
  -.601 47.794 .551 -.95158 1.58360 -4.13598 2.23282 
CON6PRE 
Equal 
variances 
assumed 
3.663 .062 1.536 42 .132 3.57510 2.32756 -1.12211 8.27231 
Equal 
variances 
not assumed 
  1.536 35.862 .133 3.57510 2.32756 -1.14604 8.29624 
CON6POST 
Equal 
variances 
assumed 
.650 .424 -.904 47 .371 -2.09189 2.31472 -6.74851 2.56473 
Equal 
variances 
not assumed 
  -.906 46.829 .370 -2.09189 2.30981 -6.73907 2.55529 
DIV4PRE 
Equal 
variances 
assumed 
1.297 .261 .280 43 .781 .27257 .97239 -1.68845 2.23359 
Equal 
variances 
not assumed 
  .279 39.279 .782 .27257 .97825 -1.70567 2.25081 
DIV4POST 
Equal 
variances 
assumed 
.909 .345 -.634 47 .529 -.64344 1.01477 -2.68489 1.39802 
Equal 
variances 
not assumed 
  -.631 44.386 .531 -.64344 1.01905 -2.69669 1.40982 
DIV6PRE 
Equal 
variances 
assumed 
2.024 .163 .482 40 .632 .65724 1.36256 -2.09659 3.41108 
Equal 
variances 
not assumed 
  .476 35.571 .637 .65724 1.37986 -2.14242 3.45691 
DIV6POST 
Equal 
variances 
assumed 
.021 .886 -1.082 44 .285 -1.42624 1.31799 -4.08248 1.23000 
Equal 
variances 
not assumed 
  -1.081 43.405 .286 -1.42624 1.31964 -4.08683 1.23435 
DSCON4PRE 
Equal 
variances 
assumed 
.210 .649 3.031 35 .005 4.52789 1.49376 1.49540 7.56037 
Equal 
variances 
not assumed 
  3.170 34.115 .003 4.52789 1.42853 1.62513 7.43065 
DSCON4POST 
Equal 
variances 
assumed 
1.397 .245 1.912 38 .063 2.58393 1.35108 -.15119 5.31906 
Equal 
variances 
not assumed 
  1.828 27.309 .078 2.58393 1.41323 -.31425 5.48211 
DSCON6PRE 
Equal 
variances 
assumed 
.015 .903 2.495 31 .018 5.74744 2.30348 1.04947 10.44542 
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Equal 
variances 
not assumed 
  2.479 27.465 .020 5.74744 2.31885 .99331 10.50158 
DSCON6POST 
Equal 
variances 
assumed 
.324 .573 2.143 38 .039 3.63786 1.69755 .20135 7.07438 
Equal 
variances 
not assumed 
  2.110 32.497 .043 3.63786 1.72451 .12726 7.14846 
DSDIV4PRE 
Equal 
variances 
assumed 
.552 .462 .181 41 .857 .22387 1.23644 -2.27316 2.72090 
Equal 
variances 
not assumed 
  .186 40.972 .854 .22387 1.20593 -2.21161 2.65935 
DSDIV4POST 
Equal 
variances 
assumed 
.230 .634 .482 44 .632 .73592 1.52601 -2.33955 3.81140 
Equal 
variances 
not assumed 
  .471 36.999 .640 .73592 1.56217 -2.42934 3.90119 
DSDIV6PRE 
Equal 
variances 
assumed 
.026 .872 .875 39 .387 1.38788 1.58607 -1.82026 4.59601 
Equal 
variances 
not assumed 
  .876 36.749 .387 1.38788 1.58513 -1.82464 4.60039 
DSDIV6POST 
Equal 
variances 
assumed 
1.923 .173 -.399 41 .692 -.68242 1.71000 -4.13583 2.77099 
Equal 
variances 
not assumed 
  -.386 32.477 .702 -.68242 1.76868 -4.28302 2.91818 
SAC5PRE 
Equal 
variances 
assumed 
.003 .954 -1.563 48 .125 -12.70565 8.12723 -29.04654 3.63525 
Equal 
variances 
not assumed 
  -1.563 47.983 .125 -12.70565 8.12723 -29.04669 3.63540 
SAC5POST 
Equal 
variances 
assumed 
2.248 .140 -1.666 48 .102 -12.79746 7.68210 -28.24335 2.64843 
Equal 
variances 
not assumed 
  -1.666 45.021 .103 -12.79746 7.68210 -28.26980 2.67487 
SAC10PRE 
Equal 
variances 
assumed 
.585 .448 -1.524 48 .134 -19.92773 13.07412 -46.21501 6.35955 
Equal 
variances 
not assumed 
  -1.524 46.966 .134 -19.92773 13.07412 -46.22998 6.37452 
SAC10POST 
Equal 
variances 
assumed 
11.750 .001 -.945 48 .349 -12.30740 13.02432 -38.49456 13.87976 
Equal 
variances 
not assumed 
  -.945 39.982 .350 -12.30740 13.02432 -38.63090 14.01611 
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Table C4 A table of statistical results from an Unpaired T-Test between therapy groups 
(OBPT vs OBVAT) performed for all movements, before and after therapy for each 
movement’s Final Amplitude. The tests with statistical significance are highlighted in 
green. 
 
Final Amplitude 
 
Levene's Test 
for Equality of 
Variances 
t-test for Equality of Means 
F Sig. t df 
Sig. 
(2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
CON4PRE 
Equal 
variances 
assumed 
6.924 .012 -.036 44 .972 -.00431 .12064 -.24743 .23882 
Equal 
variances 
not assumed 
  -.036 35.665 .972 -.00431 .12064 -.24905 .24044 
CON4POST 
Equal 
variances 
assumed 
.138 .712 -3.228 47 .002 -.34448 .10673 -.55919 -.12978 
Equal 
variances 
not assumed 
  -3.226 46.739 .002 -.34448 .10680 -.55937 -.12960 
CON6PRE 
Equal 
variances 
assumed 
4.473 .041 -.349 41 .729 -.09249 .26495 -.62757 .44260 
Equal 
variances 
not assumed 
  -.345 33.432 .732 -.09249 .26770 -.63686 .45188 
CON6POST 
Equal 
variances 
assumed 
5.851 .019 -3.444 47 .001 -.63955 .18569 
-
1.01311 
-.26598 
Equal 
variances 
not assumed 
  -3.402 33.926 .002 -.63955 .18798 
-
1.02159 
-.25750 
DIV4PRE 
Equal 
variances 
assumed 
1.236 .272 -1.518 43 .136 -.21301 .14030 -.49595 .06993 
Equal 
variances 
not assumed 
  -1.511 40.532 .138 -.21301 .14095 -.49776 .07174 
DIV4POST 
Equal 
variances 
assumed 
.178 .675 -3.310 47 .002 -.25053 .07570 -.40282 -.09824 
Equal 
variances 
not assumed 
  -3.316 46.862 .002 -.25053 .07555 -.40253 -.09854 
DIV6PRE 
Equal 
variances 
assumed 
10.919 .002 -.063 40 .950 -.01594 .25277 -.52681 .49493 
Equal 
variances 
not assumed 
  -.061 27.815 .952 -.01594 .26004 -.54877 .51689 
DIV6POST 
Equal 
variances 
assumed 
6.117 .017 -3.448 45 .001 -.56105 .16273 -.88881 -.23328 
Equal 
variances 
not assumed 
  -3.363 35.927 .002 -.56105 .16684 -.89943 -.22266 
DSCON4PRE 
Equal 
variances 
assumed 
2.290 .139 -.828 34 .413 -.24007 .28981 -.82904 .34889 
Equal 
variances 
not assumed 
  -.902 32.879 .374 -.24007 .26620 -.78174 .30159 
DSCON4POST 
Equal 
variances 
assumed 
2.625 .113 .998 39 .325 .20732 .20781 -.21302 .62766 
Equal 
variances 
not assumed 
  .915 23.660 .370 .20732 .22666 -.26084 .67549 
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DSCON6PRE 
Equal 
variances 
assumed 
2.675 .112 -.228 32 .821 -.04722 .20706 -.46899 .37455 
Equal 
variances 
not assumed 
  -.207 18.580 .838 -.04722 .22823 -.52564 .43119 
DSCON6POST 
Equal 
variances 
assumed 
.156 .695 -.325 36 .747 -.06686 .20558 -.48380 .35008 
Equal 
variances 
not assumed 
  -.326 32.858 .746 -.06686 .20491 -.48383 .35011 
DSDIV4PRE 
Equal 
variances 
assumed 
2.238 .144 4.946 34 .000 1.64502 .33259 .96911 2.32093 
Equal 
variances 
not assumed 
  5.173 32.958 .000 1.64502 .31800 .99801 2.29203 
DSDIV4POST 
Equal 
variances 
assumed 
2.993 .092 4.329 39 .000 1.58960 .36719 .84690 2.33231 
Equal 
variances 
not assumed 
  4.369 35.435 .000 1.58960 .36386 .85126 2.32795 
DSDIV6PRE 
Equal 
variances 
assumed 
6.038 .019 -.163 39 .871 -.07786 .47640 
-
1.04147 
.88574 
Equal 
variances 
not assumed 
  -.173 36.885 .863 -.07786 .44939 -.98850 .83278 
DSDIV6POST 
Equal 
variances 
assumed 
.168 .684 -1.025 43 .311 -.49635 .48427 
-
1.47297 
.48027 
Equal 
variances 
not assumed 
  -1.028 41.292 .310 -.49635 .48286 
-
1.47130 
.47860 
SAC5PRE 
Equal 
variances 
assumed 
.863 .357 -2.838 48 .007 -.32731 .11532 -.55919 -.09544 
Equal 
variances 
not assumed 
  -2.838 47.390 .007 -.32731 .11532 -.55927 -.09536 
SAC5POST 
Equal 
variances 
assumed 
.002 .969 -1.425 48 .161 -.14337 .10063 -.34571 .05896 
Equal 
variances 
not assumed 
  -1.425 47.999 .161 -.14337 .10063 -.34571 .05896 
SAC10PRE 
Equal 
variances 
assumed 
.647 .425 -3.911 48 .000 -.84210 .21529 
-
1.27496 
-.40923 
Equal 
variances 
not assumed 
  -3.911 44.969 .000 -.84210 .21529 
-
1.27572 
-.40847 
SAC10POST 
Equal 
variances 
assumed 
.732 .396 -1.889 48 .065 -.30931 .16372 -.63850 .01988 
Equal 
variances 
not assumed 
  -1.889 45.304 .065 -.30931 .16372 -.63900 .02038 
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APPENDIX D 
PAIRED T-TESTS 
 
Table D1 A table of statistical results from a Paired T-Test between before and after OBPT 
performed for all movements, for each movement’s Latency. The tests with statistical 
significance are highlighted in green. 
 
Latency 
 t df 
Sig. 
(2-tailed) 
CON4 2.299 22 .031 
CON6 1.980 21 .061 
DIV4 1.598 21 .125 
DIV6 1.824 20 .083 
DSCON4 1.186 12 .259 
DSCON6 .574 11 .578 
DSDIV4 .549 17 .590 
DSDIV6 1.711 14 .109 
SAC5 1.367 24 .184 
SAC10 1.373 24 .182 
 
Table D2 A table of statistical results from a Paired T-Test between before and after 
OBVAT performed for all movements, for each movement’s Latency. The tests with 
statistical significance are highlighted in green. 
 
Latency 
 t df 
Sig. 
(2-tailed) 
CON4 1.990 23 .059 
CON6 1.810 20 .085 
DIV4 -1.120 21 .275 
DIV6 -.530 19 .602 
DSCON4 1.207 20 .241 
DSCON6 1.006 19 .327 
DSDIV4 .252 23 .804 
DSDIV6 -1.088 21 .289 
SAC5 2.089 24 .047 
SAC10 5.183 24 .000 
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Table D3 A table of statistical results from a Paired T-Test between before and after OBPT 
performed for all movements, for each movement’s Time to Peak Velocity. The tests with 
statistical significance are highlighted in green. 
 
Time to Peak Velocity 
 t df 
Sig. 
(2-tailed) 
CON4 2.615 22 .016 
CON6 1.416 21 .172 
DIV4 1.452 21 .161 
DIV6 .868 18 .397 
DSCON4 .192 11 .851 
DSCON6 -.397 10 .700 
DSDIV4 -2.702 18 .015 
DSDIV6 -.571 16 .576 
SAC5 1.735 24 .096 
SAC10 1.323 24 .198 
 
Table D4 A table of statistical results from a Paired T-Test between before and after 
OBVAT performed for all movements, for each movement’s Time to Peak Velocity. The 
tests with statistical significance are highlighted in green. 
 
Time to Peak Velocity 
 t df 
Sig.  
(2-tailed) 
CON4 3.627 23 .001 
CON6 3.655 21 .001 
DIV4 1.974 21 .062 
DIV6 .299 18 .768 
DSCON4 .670 21 .510 
DSCON6 .573 19 .574 
DSDIV4 .882 23 .387 
DSDIV6 2.223 22 .037 
SAC5 2.610 24 .015 
SAC10 4.964 24 .000 
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Table D5 A table of statistical results from a Paired T-Test between before and after OBPT 
performed for all movements, for each movement’s Peak Velocity. The tests with statistical 
significance are highlighted in green. 
 
Peak Velocity 
 t df 
Sig.  
(2-tailed) 
CON4 -3.041 22 .006 
CON6 -2.058 21 .052 
DIV4 -2.276 22 .033 
DIV6 -1.439 20 .165 
DSCON4 -.719 10 .489 
DSCON6 -.980 12 .346 
DSDIV4 -2.134 17 .048 
DSDIV6 -.187 15 .854 
SAC5 -.686 24 .499 
SAC10 -.929 24 .362 
 
Table D6 A table of statistical results from a Paired T-Test between before and after 
OBVAT performed for all movements, for each movement’s Peak Velocity. The tests with 
statistical significance are highlighted in green. 
 
Peak Velocity 
 t df 
Sig. 
(2-tailed) 
CON4 -4.180 23 .000 
CON6 -4.490 21 .000 
DIV4 -6.070 21 .000 
DIV6 -5.036 19 .000 
DSCON4 -1.994 21 .059 
DSCON6 -2.220 17 .040 
DSDIV4 -1.912 23 .068 
DSDIV6 -2.531 21 .019 
SAC5 -1.156 24 .259 
SAC10 -.074 24 .942 
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Table D7 A table of statistical results from a Paired T-Test between before and after OBPT 
performed for all movements, for each movement’s Final Amplitude. The tests with 
statistical significance are highlighted in green. 
 
Final Amplitude 
 t df 
Sig. (2-
tailed) 
CON4 .480 22 .636 
CON6 -.050 21 .960 
DIV4 -.100 22 .921 
DIV6 .227 20 .822 
DSCON4 -.031 11 .976 
DSCON6 .028 12 .978 
DSDIV4 -1.029 18 .317 
DSDIV6 -.152 16 .881 
SAC5 .336 24 .740 
SAC10 -2.215 24 .037 
 
Table D8 A table of statistical results from a Paired T-Test between before and after 
OBVAT performed for all movements, for each movement’s Final Amplitude. The tests 
with statistical significance are highlighted in green. 
 
Final Amplitude 
 t df 
Sig. 
(2-tailed) 
CON4 -2.112 22 .046 
CON6 -1.709 20 .103 
DIV4 -.108 21 .915 
DIV6 -1.793 19 .089 
DSCON4 2.274 20 .034 
DSCON6 -.286 17 .778 
DSDIV4 -1.123 12 .283 
DSDIV6 -1.089 22 .288 
SAC5 1.878 24 .073 
SAC10 .479 24 .636 
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APPENDIX E 
BEHAVIORAL PLOTS 
 
 
Figure E1 Behavioral plots of eye movements for CON4 and DIV4. The top row is the 
four-degree convergence movements, the bottom row is the four-degree divergence 
movements. The first column is a typical OBVAT participant. The middle column is the 
OBVAT participant with the most visible change. The last column is a typical OBPT 
participant. The dashed lines are the velocity plots, and the solid lines are the position 
plots. The blue lines are before therapy, and the red lines are after therapy. 
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Figure E2 Behavioral plots of eye movements for DSCON4 and DSDIV4. The top row 
is the four-degree disappearing convergence movements, the bottom row is the four-
degree disappearing divergence movements. The first column is a typical OBVAT 
participant. The middle column is the OBVAT participant with the most visible change. 
The last column is a typical OBPT participant. The dashed lines are the velocity plots, 
and the solid lines are the position plots. The blue lines are before therapy, and the red 
lines are after therapy. 
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Figure E3 Behavioral plots of eye movements for SAC5 and SAC10. The top row is the 
five-degree saccadic movements, the bottom row is the ten-degree saccadic movements. 
The first column is a typical OBVAT participant. The middle column is the OBVAT 
participant with the most visible change. The last column is a typical OBPT participant. 
The dashed lines are the velocity plots, and the solid lines are the position plots. The blue 
lines are before therapy, and the red lines are after therapy. 
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